4530:TSEHisamitsu Pharmaceutical Co., Inc. Analysis

Honyi International trades at TWD 31.4, comfortably above its 20‑day (≈28.85), 50‑day (≈28.81) and 200‑day (≈29.65) simple moving averages, indicating short‑term price strength. The technical picture is mixed: the MACD is bullish (line +0.31, histogram +0.31) while the RSI sits at 67, edging toward overbought territory, and volume has been decreasing, suggesting waning momentum as the price approaches the nearby resistance of TWD 31.6. Fundamentally, the company is fragile – it reports a negative profit margin of –14.5%, a ROE of –24%, operating cash flow of –TWD 33.5 M and free cash flow of –TWD 18.9 M, and its PE ratio is effectively zero due to losses. Despite a solid cash buffer (TWD 182.6 M) and modest debt‑to‑equity (≈28.6%), the high 30‑day volatility of 38.7% and a max drawdown of –27.8% amplify risk. The price‑to‑book of 3.64, combined with a lack of dividend, points to an overvalued valuation relative to its weak earnings profile.